Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes

Minh Quan Duc Nguyen, Khoa Dang Dang Tran, Son Kim Tran

Open source

DOI
10.1097/md.0000000000050589
Published
2026-09-11
Container
Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/md.0000000000050589,
  title = {Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes},
  author = {Minh Quan Duc Nguyen and Khoa Dang Dang Tran and Son Kim Tran},
  year = {2026},
  journal = {Medicine},
  doi = {10.1097/md.0000000000050589},
  url = {https://doi.org/10.1097/md.0000000000050589}
}

RIS

TY  - JOUR
TI  - Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes
AU  - Minh Quan Duc Nguyen
AU  - Khoa Dang Dang Tran
AU  - Son Kim Tran
PY  - 2026
JO  - Medicine
DO  - 10.1097/md.0000000000050589
UR  - https://doi.org/10.1097/md.0000000000050589
ER  - 

APA

Nguyen, M. Q. D., Tran, K. D. D., & Tran, S. K. (2026). Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes. Medicine. https://doi.org/10.1097/md.0000000000050589

Source records